Concerns Over Dengue Vaccine DengiAll

#GS-2 #Health #Governance & Social Justice #Science & Technology #Current Events #National #Gujarat

Why in News

Serious worries surround India's upcoming DengiAll vaccine following recent safety issues during Brazil's immunization drive with Butantan-DV.
The suspension of the campaign in Brazil after tragic deaths brings the risks of antibody-dependent enhancement (ADE) into sharp focus.
Medical experts emphasize the urgent need for strict tracking of vaccine safety and comprehensive checks on tetravalent vaccine efficacy.

Dengue vaccines are special biological shots created to guard the human body against the mosquito-spread dengue virus (DENV).
Because the virus has four distinct strains named DENV-1, DENV-2, DENV-3, and DENV-4, a successful shot must be tetravalent.
A tetravalent formula must trigger equal and simultaneous immunity against all four viral varieties to be truly effective.

DengiAll is developed by Panacea Biotec alongside ICMR, and its Phase 3 trials completed enrollment in Jan 2026 while awaiting approval.
Butantan-DV from Instituto Butantan in Brazil faced a rollout suspension on June 8, 2026, following 42 serious adverse events and 2 deaths.
Qdenga is made by Takeda in Japan, and experts report that its approval from Indian regulators is coming very soon.
Dengvaxia by Sanofi Pasteur holds the title of the first licensed dengue shot, but it faced suspension in the Philippines after severe late-stage problems.

Dengue viruses use outer envelope (E) proteins to attach themselves to human cells and start an infection inside the body.
Getting vaccinated triggers the creation of both type-specific antibodies and cross-reactive antibodies to fight future infections.
Type-specific antibodies focus on one precise serotype and neutralize that exact strain to give strong and lasting protection.
Cross-reactive antibodies can bind to all four viral strains, but they are often produced in much larger quantities with lower precision.
When cross-reactive antibody levels drop over time, they become too weak to fully neutralize the incoming virus.
This dangerous drop triggers antibody-dependent enhancement (ADE), where weak antibodies help the virus enter immune cells more easily to cause severe illness.

Both DengiAll and Butantan-DV rely on a live-attenuated platform using weakened live viruses to build immune memory safely.
The manufacturing process involves physically mixing all four weakened serotypes together to build simultaneous immunity against every strain.
Physical mixing can lead to viral interference, where one strain multiplies faster and suppresses the growth of weaker strains.
Clinical trials in Brazil lacked active circulation of DENV-3 and DENV-4, leaving real-world protection levels for those strains uncertain.

Live-attenuated vaccines contain a weakened version of a pathogen that can copy itself slightly without making healthy people sick.
Because they closely copy natural infections, these shots stimulate strong immunity and need fewer booster doses over time.
Common examples include the MMR shot for measles, mumps, and rubella, along with vaccines for varicella and yellow fever.
Key limitations include unsuitability for immunocompromised individuals, strict needs for cold-chain storage, and rare risks of turning virulent again.